Servier announced a definitive agreement to acquire Day One Biopharmaceuticals for $21.50 per share in cash, representing a total equity value of approximately $2.5 billion2
The offer price represents a 68% premium over Day One's closing price on March 5, 2026, and an 86% premium over the one-month volume weighted average price2
The transaction is expected to close in the second quarter of 2026, subject to customary closing conditions including U.S. antitrust clearance and shareholder approval2
Servier will fund the acquisition through existing cash and investments2
The acquisition strengthens Servier's rare oncology position, particularly in pediatric low-grade glioma, and expands its oncology pipeline with programs ranging from early stage to phase 34
Day One's Board of Directors recommends shareholders tender their shares in the offer2
Servier will commence a cash tender offer for all outstanding shares, with any remaining shares acquired through a second-step merger at the same per-share price2
Sources:
2. https://servier.com/en/newsroom/acquisition-day-one-biopharmaceuticals-rare-oncology/
4. https://www.globenewswire.com/news-release/2026/03/06/3251033/0/en/Servier-and-Day-One-Biopharmaceuticals-announce-acquisition-to-expand-Servier-s-rare-oncology-portfolio.html